the case study of vanitas youtube

Opening Theme

Ending Theme

Recent News

North American Anime & Manga Releases For December

Here are the North American anime, manga, and light novel releases* for December. Week 1: December 6 - 12 Anime Releases Gekkan Shoujo Nozaki-kun (Monthly Girls'... read more

Dec 13, 2022 3:17 PM by Aiimee | Discuss (1 comment)

PV Collection June 21 - 27

Here is a collection of promotional videos (PV), television ads (CM), and trailers for the last week. This thread excludes videos that have already been featured in ... read more

Jun 27, 2021 3:04 PM by Snow | Discuss (1 comment)

Recent Forum Discussion

More Top Anime

• 1 Sousou no Frieren
• 2 Fullmetal Alchemist: Brotherhood
• 3 Steins;Gate
• 5 Shingeki no Kyojin Season 3 Part 2

More Top Airing Anime

• 1 Monogatari Series: Off & Monster Season
• 2 One Piece
• 3 "Oshi no Ko" 2nd Season
• 4 Doupo Cangqiong: Nian Fan
• 5 Make Heroine ga Oosugiru!

More Most Popular Characters

• 1 Lamperouge, Lelouch
• 3 Monkey D., Luffy
• 4 Lawliet, L
• 5 Roronoa, Zoro

• Subbed Anime
• Dubbed Anime

Most Popular

• HiAnime App
• Martial Arts
• Psychological
• Slice of Life
• Super Power
• Supernatural

The Case Study of Vanitas

to your friends

More Seasons

Characters & voice actors.

Archiviste, Noé

Ishikawa, Kaito

Hanae, Natsuki

Recommended for you.

Welcome to the Ballroom

Ace of Diamond Act II

Fruits Basket 1st Season

Fighting Spirit: Mashiba vs. Kimura

The Disastrous Life of Saiki K. Final Arc

Hinamatsuri

Hunter x Hunter: Greed Island

InuYasha: The Final Act

Major: Message

xxxHOLiC Rou

Berserk: The Golden Age Arc III - The Advent

Bungo Stray Dogs 2

Card Captor Sakura Movie 2: The Sealed Card

Beyond the Boundary: I'll Be Here Movie 2 - Future

Aria the Natural

One Piece: Episode of Merry - The Tale of One More Friend

Food Wars! The Third Plate

One Piece: The Movie 10 - Strong World

Naruto: Shippuden

Jujutsu Kaisen 2nd Season

Black Clover

Demon Slayer: Kimetsu no Yaiba Swordsmith Village Arc

Boruto: Naruto Next Generations

Jujutsu Kaisen (TV)

Spy x Family

• Terms of service

© HiAnime.to. All rights reserved.

Welcome back!

Create an account, reset password, send verification email.

Search for movies, TV shows, channels, sports teams, streaming services, apps, and devices.

The Case Study of Vanitas (2021)

How to stream the case study of vanitas online, about the case study of vanitas.

In 19th-century Paris, young vampire Noé finds the Book of Vanitas in human hands. Calling himself Vanitas, this doctor wields its power and tempts Noé with a plan to “cure” all vampires. Allying with him may be dangerous, but does he have a choice?

Suggested Shows

The Streamable uses the TMDb API but is not endorsed or certified by TMDb.

The Streamable uses JustWatch data but is not endorsed by JustWatch.

DIRECTV STREAM Cash Back

Let us know your e-mail address to send your $50 Amazon Gift Card when you sign up for DIRECTV STREAM.

You will receive it ~2 weeks after you complete your first month of service.

Offer Terms

• Only valid for new DIRECTV STREAM subscribers.
• Only valid once per household.
• You must pay and maintain service for at least one month to be eligible.
• Purchase must be completed on the DIRECTV STREAM website.
• You’ll receive gift card 4-6 weeks after purchase (~2 weeks after your first month).
• Cannot be combined with any other promotion and won’t be eligible if you try to use a coupon code or cash back from another site.

Sling TV Cash Back

Let us know your e-mail address to send your $25 Uber Eats Gift Card when you sign up for Sling TV.

• Only valid for new Sling TV subscribers to Sling Orange, Blue, or Sling Orange + Blue.
• You must click from The Streamable and complete your purchase on the Sling TV website.

Hulu Live TV Cash Back

Let us know your e-mail address to send your $35 Amazon Gift Card when you sign up for Hulu Live TV.

• Only valid for new Hulu Live TV subscribers.
• You must click from The Streamable and complete your purchase on the Hulu Live TV website.

Update your web browser!

Oh no! It looks like you’re using a web browser we don’t support! Please consider updating your internet browser to unlock thousands of anime titles!

Advertisement

Case Study: Patient with Metastatic Urothelial Carcinoma Has No Remaining Evidence of Disease

Treatment involved checkpoint inhibitor, surgery and intravesical therapy

Historically, metastatic upper track urothelial cancer had a poor prognosis, with survival often less than a month. After undergoing standard chemotherapy for the disease with only a marginal response, a man in his 60s came to Cleveland Clinic Cancer Center for treatment. The disease had already spread to his lymph nodes, liver and lungs.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A team of clinicians met to discuss the patient. Medical oncologist Timothy Gilligan, MD , started the patient on the antibody drug conjugate enfortumab vedotin. The patient became an early participant in a trial of the medication, which is now FDA approved for treating advanced urothelial cancer.

The treatment has a different mechanism than standard chemotherapy. With this treatment, a monoclonal antibody to nectin protein, which is prevalent in urothelial cancer, and then releases the chemotherapy to kill those cells. In this way, the drug is delivered closer to the source of cancer cells, providing somewhat less toxicity than standard chemotherapy. The patient had a considerable response to this treatment.

"Clinical trials were just starting at the time the patient began treatment with enfortumab vedotin," says Cleveland Clinic Director of Urologic Oncology Christopher Weight, MD .

"Now that the trials have matured, they've shown that on average, patients have longer survival. It seems there is a subset of patients with a combination of immunotherapy and chemotherapy that have longer term survival and response rates."

Although this patient had a robust response to the treatment, the tumor in his left kidney remained. The team then consulted together, met with the patient and decided on consolidation surgery. Dr. Weight performed the nephroureterectomy laparoscopically.

This robot-assisted procedure involved removal of the kidney, most of the ureter as well as lymph nodes. Due to the antibody drug conjugate treatment the patient had, the lymph nodes that were removed no longer showed signs of cancer.

Roughly five years later, the patient had a recurrence, with several tumors in his bladder.

"This type of cancer is notorious for growing where it lands," explains Dr. Weight. "It started in his kidneys but over time, microscopic cells were washing down into the bladder."

Drs. Gilligan and Weight consulted with a wider team in their Tumor Board about the appropriate approach and the patient's needs. "We've discussed his case several times because he kept breaking traditional paradigms," says Dr. Weight. "We found it crucial to have clear communication boundaries, multi-departmental understanding of the tools needed at each point in the disease state as well as a determination of which clinician had the right tools to best serve the patient.”

The team felt that bladder management would be the next appropriate step, and the patient underwent surgery to ablate the cancer cells. Several weeks after the procedure, the team administered intravesical therapy for the subsequent six weeks. This therapy stimulates the immune system as a preventative measure to stave off additional tumor cells.

The patient fared well. However, several months later, he experienced a recurrence in the bladder, and received additional surgery and intravesical therapy. In the latest CT scan and cystoscopy performed afterwards, there was no evidence of disease. "It was a joyous and a solemn moment when I met with him and his wife," says Dr. Weight. "This is the first time in a long time that he's not having any sort of cancer treatment."

The patient will continue to receive maintenance intravesical therapy every six months as a protective measure, with regular scans and cystoscopies performed every three months. "It's incredible that this man who was given months to live is actually disease free," says Dr. Weight.

Related Articles

Studies Evaluate Anti-Complement Inhibitors for Treating Paroxysmal Nocturnal Hemoglobinuria

Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials

Understanding the Role of Palliative Care in AL Amyloidosis

Multi-specialty coordination essential for improving quality of life

DCISionRT Decision Score Predicts the Need of Radiation Therapy for Treating Ductal Carcinoma in Situ

Seven-gene biosignature becomes first effective means to reduce over- and under-treatment with radiation therapy

Analysis From Large, Prospective Randomized Trial Finds Need for Ongoing Lymphedema Surveillance

Early intervention helps prevent chronic lymphedema

Emerging Second- and Third-Line Treatments Improve Outcomes in Diffuse Large B-Cell Lymphoma

CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management

New Research Highlights Novel Risk Stratification Model for Soft Tissue and Uterine Leiomyosarcoma

Approach could help clinicians identify patients at an increased risk of progression who could benefit from more aggressive treatment

Evaluating Risk Scores for Triple-Negative Breast Cancer in Black Women (Podcast)

Polygenic risk score could help predict who will develop this aggressive breast cancer

Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’